STOCK TITAN
  1. Home
  2. News
  3. THTX

Theratechnologies to Present at the Canaccord Genuity 42nd Annual Growth Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

MONTREAL, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10, 2022 at 1:00 p.m. ET.

A live webcast of the event can be accessed here and through the investor relations section of the Company’s website under ‘Events’. An archive will also be available for 90 days following the conference.

About Theratechnologies

Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR at www.sedar.com and on EDGAR at www.sec.gov.


Stock THTX logo
Theratechnologies Inc. Common

NASDAQ:THTX

THTX Rankings

#4650 Ranked by Market Cap
#5441 Ranked by Stock Gains
N/A Ranked by Dividends

THTX Latest News

May 2, 2024
Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting
Apr 15, 2024
Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders
Apr 11, 2024
Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Apr 10, 2024
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024
Apr 8, 2024
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform

THTX Stock Data

58.85M
34.20M
6.29%
50.89%
0.03%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Montreal

About THTX

theratechnologies inc., a biopharmaceutical company, markets prescription products in the united states, europe, and canada. it offers egrifta and egrifta sv, for the reduction of excess abdominal fat in human immunodeficiency virus (hiv)-infected patients with lipodystrophy; and trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant hiv-1 infected patients. the company's pipeline products include f8 formulation that could be used for the treatment of hiv-associated lipodystrophy; th-1902 for the treatment of triple negative breast cancer; and th-1904 for the treatment of ovarian cancer. the company was founded in 1993 and is headquartered in montreal, canada.